BIOSANTE PHARMACEUTICALS INC Form SC 13G/A February 17, 2004

OMB APPROVAL

OMB Number: 3235-0145 Expires: December 31, 2005 Estimated average burden hours per response.....11

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3)*

BIOSANTE PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK, \$0.0001 PAR VALUE

(Title of Class of Securities)

09065 V 20 3

(CUSIP Number)

DECEMBER 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [] Rule 13d-1(b) [] Rule 13d-1(c)
- [X] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

CUSIP N	10. 09065 V 20 3				
1.	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).				
	Victor A. Morgenst	tern			
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) []				
	(b) [] (d)				
3.	SEC Use Only				
4.	Citizenship or Place of Organization				
	United States of A	America			
Number of		5.	Sole Voting Power		
Shares			537,777 (see Item 4)		
Beneficially		6.	Shared Voting Power		
Owned by			527,500 (see Item 4)		
	Each	7.	Sole Dispositive Power		
Reporting			537,777 (see Item 4)		
Person With:		8.	Shared Dispositive Power		
			527,500 (see Item 4)		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	1,065,277 (see Ite	em 4)			
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
	Not Applicable				
11.	11. Percent of Class Represented by Amount in Row (9)				
	7.7%				
12.	Type of Reporting Person (See Instructions)				

Page 2 of 5

ITEM 1(a).	NAME OF ISSUER:			
	The nam	e of the i	ssuer is BioSante Pharmaceuticals, Inc.	
ITEM 1(b).	ADDRESS	OF ISSUER	'S PRINCIPAL EXECUTIVE OFFICES:	
			e principal executive offices of BioSante is vard, Lincolnshire, Illinois 60069.	
ITEM 2(a).	NAME OF	PERSON FI	LING:	
			. 3 to Schedule 13G is being filed by and on A. Morgenstern.	
ITEM 2(b).	ADDRESS	OR PRINCI	PAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:	
	is c/o	Harris Ass	. Morgenstern's principal place of business ociates, LP, 2 North LaSalle Street, Suite inois 60602.	
ITEM 2(c).	CITIZEN	SHIP:		
	Mr. Mor	genstern i	s a United States citizen.	
ITEM 2(d).	TITLE OF CLASS OF SECURITIES:			
	is the		ty securities to which this Statement relates ck, \$0.0001 par value per share, of BioSante Inc.	
ITEM 2(e).	CUSIP N	UMBER:		
	The CUS	IP number	of the common stock is 09065 V 20 3.	
ITEM 3.			IS FILED PURSUANT TO RULES 13D-1(b), OR CHECK WHETHER THE FILING PERSON IS A:	
	(a)	[]	Broker or dealer registered under Section 15 of the Securities Exchange Act of 1934 (the "Act").	
	(b)	[]	Bank, as defined in Section 3(a)(6) of the Act.	
	(c)	[]	Insurance company, as defined in Section 3(a)(19) of the Act.	
	(d)	[]	Investment company registered under Section 8 of the Investment Company Act of 1940.	
	(e)	[]	An investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E).	
	(f)	[]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).	

Page 3 of 5

- (h) [] A savings association, as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) [] A church plan, that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
- (j) [] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP:

- Amount beneficially owned: Mr. Morgenstern's beneficial (a) ownership includes: (1) 356,277 shares of common stock; (2) 171,500 shares of common stock issuable upon exercise of a warrant; (3) 10,000 shares of common stock issuable upon exercise of stock options; (4) 102,500 shares of common stock issuable upon exercise of a warrant and 270,000 shares of common stock held by Mr. Morgenstern's wife as trustee of the Morningstar Trust, as to which Mr. Morgenstern disclaims beneficial ownership; (5) 10,000 shares of common stock issuable upon exercise of a warrant and 70,000 shares of common stock held by Mr. Morgenstern's wife, as to which Mr. Morgenstern disclaims beneficial ownership; and (6) 25,000 shares of common stock issuable upon exercise of a warrant and 50,000 shares of common stock held by Resolute Partners. Mr. Morgenstern is a partner of Resolute Partners.
- (b) Percent of class: 7.7%. The foregoing percentage is calculated based on the 13,547,905 shares of common stock reported to be outstanding by BioSante on its most recently filed quarterly report on Form 10-QSB for the quarter ended September 30, 2003.
- (c) Number of shares as to which Mr. Morgenstern has:
- ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

Not Applicable.

Page 4 of 5

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON:

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP:

Not Applicable.

ITEM 10. CERTIFICATIONS:

Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2004

/s/ Victor A. Morgenstern

Victor A. Morgenstern

Page 5 of 5